Holen Sie sich die Stockscreener-App
60.00
0.29%
-0.24
Disc Medicine Inc Aktie (IRON) Neueste Nachrichten
IRON Drops Up to 39% After FDA CRL for Bitopertin -- LEVI & KORSINSKY, LLP Investigates - marketscreener.com
Disc Medicine, Inc. $IRON Stake Trimmed by Victory Capital Management Inc. - MarketBeat
Is Disc Medicine (IRON) Pricing Attractive After Recent Pullback And DCF Valuation Gap - simplywall.st
IRON Investors Lose Up to $22/Share — LEVI & KORSINSKY, LLP Investigates Disc Medicine - Morningstar
Evaluating Disc Medicine (IRON) After Recent Share Moves And Conflicting Valuation Signals - Yahoo Finance
IRON: Phase III data for bitopertin and key pipeline readouts are expected by year-end - TradingView
Disc Medicine (IRON) Is Down 8.2% After Wider 2025 Loss and ESOP Shelf FilingHas The Bull Case Changed? - simplywall.st
Disc Medicine Stock Pre-Market (+9.8%): Sector Lift on J&J Hematology Approval - Trefis
Blue Owl Capital Holdings LP Sells 20,000 Shares of Disc Medicine, Inc. $IRON - MarketBeat
Disc Medicine prices upsized securities offering to raise total $250M - MSN
Disc Medicine, Inc. $IRON Shares Acquired by Vanguard Group Inc. - MarketBeat
Disc Medicine, Inc. (NASDAQ:IRON) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Insider Sell: William Savage Sells Shares of Disc Medicine Inc (IRON) - GuruFocus
William Jacob Savage Sells 7,378 Shares of Disc Medicine (NASDAQ:IRON) Stock - MarketBeat
Disc Medicine Lands New $20 Million Investment as FDA Sets Up Potential Q4 Catalyst - AOL.com
Disc Medicine CFO Sells $720k Worth of Shares Amid FDA Rejection - AOL.com
IRON Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
IRON: Multiple late-stage programs advance toward pivotal data and regulatory milestones in 2024 - TradingView
Disc Medicine, Inc. (NASDAQ:IRON) Short Interest Update - MarketBeat
Disc Medicine, Inc. (IRON) Stock Analysis: A 50% Potential Upside In The Biotech Sector - DirectorsTalk Interviews
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc.IRON - FinancialContent
IRON (NASDAQ: IRON) proposed insider sales including 13,093-share 12/15/2025 sale - Stock Titan
Watertown biotech cuts 20% of staff after FDA rejects rare disease drug - The Business Journals
IRON: Wells Fargo Raises Price Target for Disc Medicine | IRON S - GuruFocus
Disc Medicine (NASDAQ:IRON) Price Target Raised to $79.00 - MarketBeat
A Look At Disc Medicine (IRON) Valuation After Recent Share Price Swings - simplywall.st
Disc Medicine Refocuses On APOLLO Trial After FDA Letter For Bitopertin - Sahm
Disc Medicine (IRON) Is Up 8.6% After Wider 2025 Losses And New Shelf RegistrationWhat's Changed - Yahoo Finance
Disc Medicine (IRON) Announces Restructuring Following FDA Setba - GuruFocus
Disc Medicine announces workforce reduction and restructuring plan By Investing.com - Investing.com Australia
Disc Medicine announces workforce reduction and restructuring plan - Investing.com Nigeria
Insider Sell: Jean Franchi Sells Shares of Disc Medicine Inc (IR - GuruFocus
Disc Medicine (NASDAQ:IRON) CFO Sells $24,378.18 in Stock - MarketBeat
Disc Medicine Implements Restructuring Following FDA Response - TipRanks
Disc Medicine's board approves restructuring plan - marketscreener.com
Disc Medicine (IRON) CFO sells 353 shares under 10b5-1 plan - Stock Titan
Disc Medicine (IRON) trims workforce 20% after FDA letter, books $2M charge - Stock Titan
Disc Medicine (NASDAQ:IRON) Price Target Lowered to $83.00 at Truist Financial - MarketBeat
JPMorgan Chase & Co. Sells 90,737 Shares of Disc Medicine, Inc. $IRON - MarketBeat
Decoding Disc Medicine Inc (IRON): A Strategic SWOT Insight - GuruFocus
Disc Medicine (NASDAQ:IRON) Releases Quarterly Earnings Results - MarketBeat
Disc Medicine: Strong Cash Runway and Bitopertin Upside Support Buy Rating Despite Regulatory Setbacks - TipRanks
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc.- IRON - PR Newswire
Disc Medicine, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Disc Medicine's 2025 Net Loss Widens - marketscreener.com
Disc Medicine Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - The Manila Times
Disc Medicine, Inc. SEC 10-K Report - TradingView
Disc Medicine Reports Fourth Quarter and Full Year 2025 Financial Results - TradingView
Disc Medicine's 2025 net loss smaller than estimates - TradingView
Disc Medicine (NASDAQ: IRON) faces FDA CRL as hematology pipeline advances - Stock Titan
Disc Medicine (NASDAQ: IRON) details 2025 loss, cash runway and FDA letter - Stock Titan
After FDA setback, Disc Medicine pushes rare blood drugs with $791M cash - Stock Titan
Disc Medicine Stock Is Swinging, but This Fund's New $52 Million Bet Shows Conviction - AOL.com
Jean Franchi sells 7,081 IRON shares under 10b5-1 (IRON) - Stock Titan
Disc Medicine Stock Is Swinging, but This Fund's New $52 Million Bet Shows Conviction - The Motley Fool
Disc Medicine’s RALLY-IBD Trial Puts a Spotlight on Anemia Relief in IBD Patients - TipRanks
Opinion | Who’s in Charge at the FDA? - WSJ
0.18%
0.28%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):